To study the effect of a herbal preparation containing a standardised BNO 1040 extract* (based on lovage root, rosemary leaves and aerial parts of centaury) on the extracorporeal shockwave lithotripsy (ESWL) results in patients with urolithiasis (UL). 150 patients with UL (aged 18–65 years) treated with ESWL method were divided into 2 equal groups. The main group (n = 75) received standard recommendations and herbal preparation (12 months). The control group (n = 75) received standard recommendations only. The following was evaluated: time and degree of elimination of fragments; the presence of pain and leukocyturia; recurrent stone formation. The elimination of fragments was observed up to 14 days in 94.7% of patients in the main group versus 76% of patients in the control group. Renal colic was observed in 6.7% of patients in the main group versus 10.7% of patients in the control group; cases of leukocyturia were observed within 14 days in 10.7% versus 22.7%, respectively. During the year, a recurrent lithiasis was diagnosed in 6.7% of patients in the main group and in 16% of patients in the control group. The use of BNO 1040 extract in combination with ESWL: contributes to more rapid and safe elimination of fragments of the calculi and reduces the risk of recurrent stone formation. DRKS ID 00021200 . Registered retrospectively in German Clinical Trial Register 27.03.2020. https://www.drks.de/

中文翻译：

---

一种基于独活草，迷迭香和百日咳的草药制剂对体外冲击波碎石术的疗效

为了研究含有标准化BNO 1040提取物*（基于独活草根，迷迭香叶和百日草的空中部分）的草药制剂对尿路结石病（UL）患者体外冲击波碎石术（ESWL）的影响。将150例经ESWL方法治疗的UL患者（年龄在18-65岁之间）分为两组。主要人群（n = 75）接受了标准建议和草药准备（12个月）。对照组（n = 75）仅收到标准建议。评价以下内容：碎片消除的时间和程度；疼痛和白细胞增多症的存在；反复结石形成。在主要组的94.7％的患者中观察到长达14天的碎片消除，而在对照组中则是76％的患者。6例观察到肾绞痛。主要组的患者为7％，对照组为10.7％；在14天内观察到白细胞减少症的病例分别为10.7％和22.7％。在这一年中，主要组中有6.7％的患者被诊断出复发性石尿症，而对照组中则有16％的患者被诊断出患有结石。将BNO 1040提取物与ESWL结合使用：有助于更快，更安全地消除结石碎片，并降低结石复发的风险。卡车ID 00021200。回顾性注册于德国临床试验注册簿27.03.2020。https://www.drks.de/ 主要组中有7％的患者，对照组中有16％的患者。将BNO 1040提取物与ESWL结合使用：有助于更快，更安全地消除结石碎片，并降低结石复发的风险。卡车ID 00021200。回顾性注册于德国临床试验注册簿27.03.2020。https://www.drks.de/ 主要组中有7％的患者，对照组中有16％的患者。将BNO 1040提取物与ESWL结合使用：有助于更快，更安全地消除结石碎片，并降低结石复发的风险。卡车ID 00021200。回顾性注册于德国临床试验注册簿27.03.2020。https://www.drks.de/